NCT05453799View on ClinicalTrials.gov

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 21, 2022

Primary Completion Date

July 15, 2026

Study Completion Date

July 15, 2027

Conditions
Locally Advanced Thyroid Gland Anaplastic CarcinomaMetastatic Thyroid Gland Anaplastic CarcinomaMetastatic Thyroid Gland Oncocytic Carcinoma
Interventions
DRUG

Vudalimab

Given IV

Trial Locations (2)

60611

Northwestern University, Chicago

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER